Niki BioSolutions, Inc. lost $0.19 per diluted share in fiscal year 2025. This represents an increase of 75.6% from the prior fiscal year. The table below carries 8 fiscal years, from 2018 to 2025, and the quarters Niki BioSolutions, Inc. has filed alongside them.
FY2025 annual
EPS (Diluted)-$0.19
YoY+75.6%
Source SEC Filings (10-K/10-Q)Latest period FY2025, ended Dec 31, 2025ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
NIKI EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
What was Niki BioSolutions, Inc.'s diluted earnings per share in fiscal year 2025?
Niki BioSolutions, Inc. lost $0.19 per diluted share in fiscal year 2025.
How fast is Niki BioSolutions, Inc.'s diluted earnings per share growing?
Niki BioSolutions, Inc. (NIKI) diluted earnings per share rose by 75.6% year over year, from -$0.78 to -$0.19 in fiscal year 2025.
How has Niki BioSolutions, Inc.'s diluted earnings per share changed over the years?
Across the 8 fiscal years this page covers, Niki BioSolutions, Inc. (NIKI) diluted earnings per share went from -$0.53 in fiscal year 2018 to -$0.19 in fiscal year 2025.
What was Niki BioSolutions, Inc.'s diluted earnings per share in the most recent quarter?
Niki BioSolutions, Inc. (NIKI) reported -$0.04 in diluted earnings per share in Q4 2025. This represents an increase of 75.0% from the same quarter a year earlier.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Niki BioSolutions, Inc. (NIKI) reported on that line in every period on record.
